Chronic Kidney Disease, Contrast Induced Nephropathy, Intensive Care Unit, Pentoxifylline
Conditions
Brief summary
The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.
Detailed description
Contrast-induced acute kidney injury (AKI), which is also known as contrast-induced nephropathy (CIN), is defined as the development of AKI following contrast medium exposure, without an alternative aetiology. Recently, the cyclic nucleotide phosphodiesterase (PDE) has emerged as a promising target for pharmacological intervention against chronic kidney disease (CKD) progression. The nonselective PDE inhibitor pentoxifylline (PTX) is a methyl xanthine derivative. It's an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. In addition to its classic indication for intermittent claudication. It has been used primarily to treat patients with peripheral arterial insufficiency.
Interventions
DRUGPentoxifylline
Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day \[dose adjustment according to estimated glomerular filtration rate (eGFR)\] from 24 hr before contrast to 48 hr after contrast procedure.
DRUGNormal saline
Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 65 years. * Both sexes. * The presence of chronic kidney disease (CKD) is defined according to the National Kidney Foundation-kidney disease Outcomes Quality Initiative guidelines with second or third stage. * Urgent patients expected taking dye in stable cases of cardiac catheterization or pulmonary embolism with Geneva score (4-11).
Exclusion criteria
* Patients with CKD on renal replacement therapy. * Respiratory failure. * Cardiac failure. * Liver failure. * Methylxanthines hypersensitivity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of contrast induced nephropathy | 48 hours after contrast procedure. | Incidence of contrast induced nephropathy was recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress of glomerular filtration rate | 48 hours after contrast procedure. | Progress of glomerular filtration rate after use of pentoxifylline was recorded. |
| Lenght of intensive care unit stay | Till the end of procedure (Up to 4 hours) | Lenght of intensive care unit stay was recorded. |
| Need of dialysis | 48 hours after contrast procedure. | Need of dialysis was recorded. |
Countries
Egypt
Outcome results
None listed